The study reviewed the medical records of patients diagnosed with ROS1-rearranged non-small cell lung cancer at Beijing Chest Hospital between February 2017 and January 2025. From 99 patients identified as harboring the rearrangement, 55 met the criteria for inclusion in the final analysis. The retrospective design allowed the team to capture the full texture of routine care, including the variety of diagnostic methods used, the sequencing of treatments, and the long-term outcomes that patients actually experienced outside the constraints of clinical trial eligibility criteria. Fusion partners were characterized using molecular techniques including next-generation sequencing and real-time polymerase chain reaction, and clinical responses were evaluated according to standard RECIST criteria for solid tumors.

The most striking structural insight from the study is that CD74 emerged as the most common fusion partner gene in this cohort, confirming patterns seen in other populations. ROS1 fusions arise when the ROS1 gene breaks and fuses with a variety of partner genes, producing a constitutively activated kinase that drives uncontrolled cell growth. Different fusion partners preserve different portions of the ROS1 kinase domain and can vary in breakpoint position, and there has long been speculation in the field about whether these structural differences translate into different clinical behaviors. The Beijing data now provide concrete real-world evidence that they do, at least for one fusion partner.

Treatment patterns in the cohort reflect how thoroughly targeted therapy has displaced chemotherapy in this molecularly defined subgroup. Targeted therapy with tyrosine kinase inhibitors, drugs that directly block the aberrant ROS1 signaling machinery, accounted for 87.3 percent of first-line treatment decisions, and ultimately every patient in the study received targeted therapy at some point during their treatment course. The results were impressive by any measure: the objective response rate for first-line treatment reached 72.7 percent, meaning nearly three out of four patients saw their tumors shrink measurably, and the median progression-free survival across the cohort was 18.9 months, a substantial span of disease control in advanced lung cancer.

But when the investigators stratified outcomes by fusion subtype, a clear divide appeared. Patients whose tumors carried an SDC4 fusion partner had an objective response rate of only 44.4 percent in first-line treatment, compared with 86.1 percent for those with other fusion subtypes, a statistically significant difference. Progression-free survival told the same story: the SDC4 subgroup experienced a median progression-free survival of 7.5 months, dramatically shorter than the 22.4 months seen in patients with non-SDC4 fusions. Univariate and multivariate Cox regression analyses converged on the same conclusion, identifying SDC4 subtype as an independent prognostic factor for shorter progression-free survival on first-line therapy. The biological explanation remains an open question, but the finding suggests that the architecture of the fusion itself may influence how completely kinase inhibitors can suppress the oncogenic signal, or how quickly resistance mechanisms emerge.

Beyond fusion subtype, the study illuminated other biological markers with prognostic weight. Programmed death-ligand 1 expression, a measure of the immune-evading machinery of tumor cells, also mattered: patients with PD-L1 expression below one percent had remarkably longer median progression-free survival that had not yet been reached at the time of analysis, compared with 17.3 months for those whose tumors expressed PD-L1 at one percent or higher. Baseline metastatic site added further prognostic nuance. Patients with bone metastases at diagnosis had a median progression-free survival of just 7.5 months versus 24.2 months for those without, while for overall survival, smoking history and baseline liver metastasis each predicted markedly shorter survival, cutting median overall survival to 22.6 and 23.8 months respectively, compared with 63.2 months for patients without those risk factors.

Treatment choices themselves proved consequential in ways that reinforce current clinical thinking. Patients who received tyrosine kinase inhibitors as first-line therapy had a median progression-free survival of 22.4 months, compared with only 6.4 months for those who began with other regimens, and multivariate analysis confirmed first-line TKI use as an independent prognostic factor. Perhaps the most powerful predictor of all was the earliest signal of treatment effect: patients who responded to their initial targeted therapy lived dramatically longer without progression, 23.6 months versus 4.4 months, and their overall survival reflected this advantage, with responders living significantly longer than non-responders. The message for clinicians is unambiguous, that securing an early response with the right targeted agent sets the trajectory for the entire course of the disease.

Taken together, the survival figures offer a genuinely encouraging bottom line for this rare patient population. The median overall survival of the entire cohort reached 59.8 months, a figure that would have been unthinkable in the era before molecularly targeted lung cancer therapy, when advanced ROS1-rearranged disease was treated as an undifferentiated malignancy with cytotoxic chemotherapy. The study also demonstrated that patients benefit consistently from targeted therapy across the fusion subtype spectrum, even if the degree of benefit varies, and that the results achieved in this real-world Chinese cohort align well with the response rates reported in registration trials for ROS1 inhibitors, providing reassurance that trial outcomes translate to routine practice.

The implications for precision oncology extend well beyond the statistics. As comprehensive molecular profiling becomes standard for advanced lung cancer, this study argues that reporting should go beyond simply flagging ROS1 rearrangement as positive or negative and should instead specify the fusion partner and co-variant markers such as PD-L1 expression and metastatic pattern, because these variables together define distinct prognostic strata within what has been treated as a single molecular class. Patients with SDC4 fusions, bone metastases, or higher PD-L1 expression may warrant closer surveillance, earlier sequencing to second-generation inhibitors, or combination strategies, while those with favorable profiles can be counseled with well-founded optimism. For a biomarker that occurs in a small minority of lung cancers, ROS1 continues to punch far above its weight in shaping the future of personalized cancer medicine, and studies like this one, grounded in the messy reality of clinical care, are essential for ensuring that every patient within a molecular subgroup receives the nuance their tumor biology demands.

Subject of Research: Real-world survival outcomes of patients with advanced ROS1 fusion-positive non-small cell lung cancer

Article Title: Survival of patients with advanced non-small cell lung cancer harboring different ROS1 fusion subtypes: a real-world study

Article References: Survival of patients with advanced non-small cell lung cancer harboring different ROS1 fusion subtypes: a real-world study. (n.d.). https://doi.org/10.1186/s12885-026-16863-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16863-w

Keywords: non-small cell lung cancer, ROS1 fusion, SDC4 subtype, CD74, targeted therapy, tyrosine kinase inhibitor, progression-free survival, overall survival, PD-L1, bone metastasis, precision oncology, real-world study